APOE4 Isn’t Destiny: Reframing Risk and Focusing on Modifiable Factors in Dementia Care

In an era where genetic testing is accessible to nearly anyone with an internet connection, palliative care clinicians are increasingly encountering patients—and family members—who are anxious about their APOE4 status. Popular genetic platforms like 23andMe often alert users to their APOE4 allele status, sparking fears that a diagnosis of Alzheimer’s disease is inevitable. As frontline providers in serious illness care, we must be prepared to address these fears with clarity, accuracy, and hope grounded in science.

Let’s begin by reframing APOE4 in proper context.

Understanding the APOE4 Gene: Risk vs. Reality

APOE4 is one of three common variants of the apolipoprotein E gene, which plays a role in lipid metabolism and has been associated with Alzheimer’s disease. Carrying one copy of the APOE4 allele increases the lifetime risk of developing Alzheimer’s disease approximately 2-3 times. Two copies? The risk jumps to 8-12 times the baseline.

But what does that really mean?

When we translate those relative risks into absolute terms, the data becomes less frightening:

• General population risk of Alzheimer’s by age 85: ~10–12%
• One APOE4 copy by age 85: ~20–25%
• Two APOE4 copies by age 85: ~30–55%

Yes, the risk increases—but it’s far from a guarantee. Even those with two copies of APOE4 are still more likely not to develop Alzheimer’s than to receive a diagnosis. And this is where the real conversation begins.

Hearing Loss: A More Potent and Common Risk Factor

In contrast to APOE4, let’s look at a much more common and modifiable risk factor: hearing loss.

• Mild hearing loss: ~18–24% dementia risk
• Moderate hearing loss: ~24–36%
• Severe hearing loss: ~36–60%

Compare that to APOE4 carriers: moderate hearing loss has a comparable or greater absolute dementia risk than carrying two APOE4 alleles. Yet hearing loss is vastly more prevalent, affecting about 30% of people over 50, whereas only 2% of the population carries two APOE4 copies.

Unlike genetics, hearing loss is modifiable. It can be identified and often effectively managed with hearing aids, cochlear implants, and auditory rehabilitation. Unfortunately, hearing loss remains underdiagnosed and undertreated—especially in older adults, many of whom may already be under palliative care.

The Bigger Picture: Modifiable Risk Factors Drive Dementia

Alzheimer’s disease and other dementias are not caused by a single gene, nor are they solely dictated by heredity. Research consistently demonstrates that modifiable risk factors account for up to 40% of all dementia cases. Among the most significant contributors:

• Physical inactivity (1.8x risk)
• Social isolation (1.6x risk)
• Untreated depression (1.9x risk)
• Poor sleep quality (1.7x risk)
• Uncontrolled diabetes (1.5x risk)
• Hearing loss (as shown above)

Each of these is a potential point of intervention—particularly in palliative care, where symptom management, psychosocial support, and quality of life are already central to our goals.

Implications for Palliative Care

We as clinicians often focus on what cannot be changed: prognosis, disease progression, loss of function. But the data presented here offer a powerful reminder: even in serious illness, lifestyle factors and symptom management can influence long-term outcomes—especially cognition and quality of life.

Whether working with patients in early-stage dementia, or caring for someone nearing end-of-life who is APOE4-positive, we can:

1. Educate without fear – Help patients and families understand that APOE4 is not destiny. Most carriers never develop Alzheimer’s.
2. Emphasize what’s modifiable – Encourage exercise, social engagement, treatment for depression, hearing evaluations, and optimal diabetes control.
3. Support behavioral interventions – In early-stage dementia and even mild cognitive impairment, targeting modifiable factors can slow progression and maintain function.
4. Champion hearing health – Screening for hearing loss in older adults should be routine. The downstream cognitive benefits of hearing aid use are significant—and underutilized.
5. Normalize the conversation around cognitive health – Especially in palliative settings, this means reinforcing that many risks can be mitigated, and life can remain meaningful and connected despite illness.

The Takeaway: Shift the Narrative from Fear to Empowerment

The message for our patients, families, and even our colleagues is clear: Genetics loads the gun. Lifestyle pulls the trigger.

When patients receive news of APOE4 status, they often interpret it as a diagnosis—not just a risk. It’s up to us to help reframe that narrative. By focusing on what can be changed, we return agency to our patients and support a care model grounded not only in acceptance of decline—but in hope, prevention, and the preservation of dignity and function.

We must continue to ask: What can we modify? What can we manage? What brings meaning to this patient’s life?

And perhaps most importantly: What small changes today might preserve memory, connection, and independence tomorrow?

Let’s continue to focus on what matters—and what we can change.

References:

• Livingston G et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413-446.
• Deal JA, et al. (2017). Hearing Impairment and Incident Dementia and Cognitive Decline in Older Adults: The Health ABC Study. Journals of Gerontology, 72(5), 703–709.
• Farrer LA, et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA, 278(16), 1349–1356.